In contrast, the levels of cleaved Caspase-3 and cleaved PARP were increased (Fig. S7C), and similar results were found in our mouse HCC xenografts, where the combination of Roblitinib and CPI-169 induced more cleaved Caspase-3 than either treatment alone (Fig. 4D). The gene discussed is CASP3; the disease is hepatocellular carcinoma.